Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Myeloid 1Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 79Cisplatin 72Carboplatin 72Bevacizumab 29Radiotherapy 27Brachytherapy 23Hyperthermic Intraperitoneal Chemotherapy 20Drug Therapy 20olaparib 19Gemcitabine 17niraparib 16apatinib 16pembrolizumab 15Surgical Procedures, Operative 15liposomal doxorubicin 12Cyclophosphamide 12Surveys and Questionnaires 11camrelizumab 10Taxes 10Neoadjuvant Therapy 10fludarabine 9anlotinib 9Etoposide 9Blood Specimen Collection 9Topotecan 8Docetaxel 8Sentinel Lymph Node Biopsy 7Platinum 7Injections 7Cytoreduction Surgical Procedures 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Tyrosine Kinase Inhibitors × Gynecologic × Clear all
NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Zhongda Hospital

Phase 2 Unknown
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡